MCID: SKN013
MIFTS: 50

Skin Benign Neoplasm

Categories: Cancer diseases, Skin diseases

Aliases & Classifications for Skin Benign Neoplasm

MalaCards integrated aliases for Skin Benign Neoplasm:

Name: Skin Benign Neoplasm 12 15
Neoplasm of Skin by Site 12
Benign Neoplasm of Skin 71
Tumor of the Skin 12
Skin Neoplasms 71
Skin Tumor 54

Classifications:



External Ids:

Disease Ontology 12 DOID:3165
MeSH 44 D012878
NCIt 50 C3372
SNOMED-CT 67 126488004
ICD10 32 D23.9
UMLS 71 C0004998 C0037286

Summaries for Skin Benign Neoplasm

MalaCards based summary : Skin Benign Neoplasm, also known as neoplasm of skin by site, is related to malignant syringoma and mismatch repair cancer syndrome 1, and has symptoms including pruritus and exanthema. An important gene associated with Skin Benign Neoplasm is KRT14 (Keratin 14), and among its related pathways/superpathways are Developmental Biology and Endometrial cancer. The drugs Petrolatum and Mineral oil have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and t cells, and related phenotypes are cellular and behavior/neurological

Related Diseases for Skin Benign Neoplasm

Diseases related to Skin Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 348)
# Related Disease Score Top Affiliating Genes
1 malignant syringoma 32.1 KRT5 KRT20
2 mismatch repair cancer syndrome 1 31.9 MSH6 MSH2 MLH1
3 squamous cell papilloma 31.4 KRT14 HRAS
4 keratoacanthoma 30.8 MSH2 MLH1 KRT14
5 papilloma 30.8 TP63 ODC1 KRT5 KRT20 KRT14 KRT13
6 skin papilloma 30.6 STAT3 ODC1 KRT14 KRT1 HRAS
7 keratosis 30.5 KRT5 KRT14 KRT1 HRAS FGFR3
8 neurofibromatosis 30.5 MSH6 MSH2 MLH1 HRAS
9 squamous cell carcinoma 30.4 TP63 STAT3 PTCH1 HRAS FGFR3
10 dysplastic nevus syndrome 30.4 MSH6 MSH2 MLH1
11 eccrine acrospiroma 30.4 KRT5 KRT14
12 xeroderma pigmentosum, variant type 30.3 XPA PTCH1 MSH6 MSH2 MLH1
13 actinic keratosis 30.3 TP63 KRT20 HRAS
14 polycystic liver disease 1 with or without kidney cysts 30.3 PTCH1 KRT20 FLCN
15 eccrine porocarcinoma 30.3 STAT3 KRT5 KRT1
16 in situ carcinoma 30.2 SERPINA3 KRT5 KRT14 HRAS
17 skin melanoma 30.2 STAT3 SERPINA3 MLH1 HRAS
18 sarcomatoid carcinoma 30.2 TP63 SERPINA3 KRT20 KRT14
19 adenoma 30.2 ODC1 MSH6 MSH2 MLH1 KRT20
20 fibroma 30.1 SERPINA3 PTCH1 KRT14
21 hereditary nonpolyposis colon cancer 30.1 MSH6 MSH2 MLH1
22 muir-torre syndrome 30.1 MSH6 MSH2 MLH1
23 skin disease 30.1 TP63 SERPINA3 KRT5 KRT14 KRT1 FGFR3
24 sebaceous adenoma 30.1 SERPINA3 MSH6 MSH2 MLH1
25 skin carcinoma 30.0 XPA STAT3 PTCH1 ODC1 MSH6 MSH2
26 sebaceous adenocarcinoma 30.0 MSH6 MSH2 MLH1 KRT5 KRT14
27 melanoma, cutaneous malignant 1 30.0 MSH6 MSH2 MLH1 HRAS
28 familial adenomatous polyposis 29.9 ODC1 MSH6 MSH2 MLH1 HRAS
29 neuroblastoma 29.8 STAT3 PTCH1 ODC1 KRT1 HRAS FGFR3
30 lung cancer susceptibility 3 29.7 STAT3 MLH1 KRT20 HRAS FGFR3
31 adenocarcinoma 29.7 STAT3 MSH6 MSH2 MLH1 HRAS FGFR3
32 basal cell nevus syndrome 29.7 XPA PTCH1 KRT14 HRAS GLI2 GLI1
33 squamous cell carcinoma, head and neck 29.7 TP63 STAT3 MLH1 HRAS FGFR3
34 brain cancer 29.6 STAT3 PTCH1 HRAS GLI1
35 adenoid cystic carcinoma 29.6 TP63 STAT3 SERPINA3 KRT5 KRT20 KRT14
36 basal cell carcinoma 29.6 XPA TP63 STAT3 PTCH1 MSH2 MLH1
37 pancreatic cancer 29.3 STAT3 SERPINA3 PTCH1 MSH2 MLH1 KRT20
38 skin lipoma 11.0
39 malignant granular cell skin tumor 11.0
40 genetic skin tumor 11.0
41 rare skin tumor or hamartoma 11.0
42 keratosis, seborrheic 10.9
43 brooke-spiegler syndrome 10.8
44 birt-hogg-dube syndrome 10.8
45 ceruminous adenocarcinoma 10.5 KRT5 KRT14
46 silent pituitary adenoma 10.5 MSH6 MSH2
47 benign breast adenomyoepithelioma 10.5 KRT5 KRT14
48 breast adenomyoepithelioma 10.5 KRT5 KRT14
49 actinic cheilitis 10.5 MSH2 FGFR3
50 breast myoepithelial neoplasm 10.5 KRT5 KRT14

Graphical network of the top 20 diseases related to Skin Benign Neoplasm:



Diseases related to Skin Benign Neoplasm

Symptoms & Phenotypes for Skin Benign Neoplasm

UMLS symptoms related to Skin Benign Neoplasm:


pruritus, exanthema

MGI Mouse Phenotypes related to Skin Benign Neoplasm:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.37 FGFR3 FLCN GLA GLI1 GLI2 KRT14
2 behavior/neurological MP:0005386 10.35 FGFR3 GLA GLI1 GLI2 HRAS KRT5
3 homeostasis/metabolism MP:0005376 10.31 FGFR3 FLCN GLA GLI2 HRAS KRT1
4 growth/size/body region MP:0005378 10.3 FGFR3 FLCN GLA GLI1 GLI2 HRAS
5 digestive/alimentary MP:0005381 10.24 FGFR3 GLI1 GLI2 HRAS KRT14 KRT5
6 immune system MP:0005387 10.22 FGFR3 FLCN GLA KRT1 KRT14 KRT5
7 craniofacial MP:0005382 10.21 FGFR3 GLI1 GLI2 HRAS KRT14 KRT5
8 integument MP:0010771 10.21 FGFR3 GLI2 HRAS KRT1 KRT14 KRT5
9 mortality/aging MP:0010768 10.19 FGFR3 FLCN GLA GLI1 GLI2 HRAS
10 endocrine/exocrine gland MP:0005379 10.13 GLI1 GLI2 HRAS KRT14 MLH1 PTCH1
11 neoplasm MP:0002006 9.93 FGFR3 FLCN GLI1 HRAS KRT14 MLH1
12 limbs/digits/tail MP:0005371 9.87 FGFR3 GLI1 GLI2 KRT5 PTCH1 TP63
13 renal/urinary system MP:0005367 9.56 FGFR3 FLCN GLA GLI1 HRAS PTCH1
14 respiratory system MP:0005388 9.32 FGFR3 GLI1 GLI2 HRAS KRT14 MLH1

Drugs & Therapeutics for Skin Benign Neoplasm

Drugs for Skin Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 297)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Petrolatum Approved, Investigational Phase 4 8009-03-8
2
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
3
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
4
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 439542 10909430
5
Fluorouracil Approved Phase 4 51-21-8 3385
6
Etanercept Approved, Investigational Phase 4 185243-69-0
7
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
8
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
9
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030
10
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
11
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
12
Mycophenolic acid Approved Phase 4 24280-93-1 446541
13
Azathioprine Approved Phase 4 446-86-6 2265
14
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
15 triamcinolone acetonide Phase 4
16 Triamcinolone hexacetonide Phase 4
17 Triamcinolone diacetate Phase 4
18 Anti-Infective Agents, Local Phase 4
19 Gastrointestinal Agents Phase 4
20 Erythromycin Estolate Phase 4
21 Erythromycin stearate Phase 4
22 Erythromycin Ethylsuccinate Phase 4
23 Polymyxins Phase 4
24 Lubricant Eye Drops Phase 4
25 Tin Fluorides Phase 4
26 Immunosuppressive Agents Phase 4
27 Antirheumatic Agents Phase 4
28 Anti-Infective Agents Phase 4
29 Antifungal Agents Phase 4
30 Antibiotics, Antitubercular Phase 4
31 Anti-Bacterial Agents Phase 4
32 Neurotransmitter Agents Phase 4
33 Cyclosporins Phase 4
34 Dermatologic Agents Phase 4
35 Calcineurin Inhibitors Phase 4
36 Antimetabolites Phase 4
37 abobotulinumtoxinA Phase 4
38 Hemagglutinins Phase 4
39 Botulinum Toxins, Type A Phase 4
40 Botulinum Toxins Phase 4
41 Agglutinins Phase 4
42 Cholinergic Agents Phase 4
43
Everolimus Approved Phase 3 159351-69-6 6442177 70789204
44
Vinblastine Approved Phase 3 865-21-4 13342 241903
45
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
46
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
47
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
48
Acetaminophen Approved Phase 3 103-90-2 1983
49
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166 2942
50
Talimogene laherparepvec Approved, Experimental, Investigational Phase 3 1187560-31-1

Interventional clinical trials:

(show top 50) (show all 488)
# Name Status NCT ID Phase Drugs
1 A Randomized, Open-Label Study to Compare the Rate of New Non-Melanoma Skin Cancer in Maintenance Renal Allograft Recipients Converted to a Sirolimus-based Regimen Versus Continuation of a Calcineurin Inhibitor-based Regimen Completed NCT00129961 Phase 4 sirolimus;cyclosporine or tacrolimus
2 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
3 The Role of Topical Antibiotic Prophylaxis in Eyelid Surgery Completed NCT03199911 Phase 4 Topical Antibiotic Product;Topical Non-Antibiotic Ointment
4 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Completed NCT00847912 Phase 4 5-fluorouracil;Placebo, vehicle control
5 Photosensitivity of the Skin Under Azathioprin in Renal Transplant Recipients Completed NCT00492895 Phase 4 Discontinuation of Azathioprin
6 Efficacy of Rapamycin (Sirolimus) in the Treatment of Blue Rubber Bleb Nevus Syndrome, Hereditary or Sporadic Venous Malformation Recruiting NCT03767660 Phase 4 Rapamycin
7 Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma: a Single Arm Prospective Study Recruiting NCT04056962 Phase 4 Tacrolimus ointment
8 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4 Sirolimus
9 A Prospective, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of AbobotulinumtoxinA (BTX-A) in Improving Forehead Wounds After Mohs Micrographic Surgery and Reconstruction for Skin Cancer Terminated NCT01459666 Phase 4 Dysport (abobotulinumtoxinA);Bacteriostatic 0.9% Sodium Chloride (vehicle)
10 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT00866684 Phase 4 Sirolimus;Azathioprine;Mycophenolate;Ciclosporin;Tacrolimus
11 CERTICOEUR a Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. An Open Labelled Randomized Everolimus vs Calcineurin Inhibitors Multicenter Trial Unknown status NCT00799188 Phase 3 Everolimus
12 Phase III Randomized Study of Dacarbazine With or Without Allovectin-7 in Patients With Metastatic Melanoma Completed NCT00003647 Phase 3 allovectin-7;allovectin-7/dacarbazine;dacarbazine
13 Prospective Study To Determine Whether Tissue Scoring Results In Noticeable Marks Following Mohs Micrographic Surgery Completed NCT00367042 Phase 2, Phase 3
14 A Randomized Controlled Trial Of CHARTWEL (a Continuous Hyperfractionated Accelerated Radiotherapy Schedule) Versus Conventional Radiotherapy In Post-Operative Head And Neck Cancer Patients Completed NCT00021125 Phase 3
15 Adjuvant Therapy for Melanoma Patients With Regional Lymph Node Metastases With Interferon Alfa-2B vs. Biochemotherapy Using Cisplatin + Vinblastine + DTIC + Interferon Plus IL-2 Completed NCT00002882 Phase 3 Cisplatin;Dacarbazine;Vinblastine
16 A Randomized Control Trial of Sun Protection Interventions for Operating Engineers Completed NCT01804595 Phase 2, Phase 3
17 Prospective and Randomized Study to Evaluate Interest of Ultracision Use in Inguinal Lymph Nodes Curage. Completed NCT00224744 Phase 3
18 Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients - Multicentric Randomized, Open-label Study of Rapamycin vs Calcineurin Inhibitors Completed NCT00133887 Phase 3 rapamycin;ciclosporine;tacrolimus
19 A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma Completed NCT00110019 Phase 3 Carboplatin;Paclitaxel;Sorafenib Tosylate
20 A Randomized Controlled Trial of Excisional Surgery Versus Imiquimod 5% Cream for Nodular and Superficial Basal Cell Carcinoma Completed NCT00066872 Phase 3 imiquimod
21 Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy in High-risk Cutaneous Squamous Cell Carcinoma of the Head and Neck Completed NCT00193895 Phase 3 Carboplatin
22 A Randomized, Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With "No Evidence of Disease" After Complete Surgical Resection of "Locally Advanced" and/or Stage IV Melanoma Completed NCT01989572 Phase 3
23 A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma Completed NCT00019682 Phase 3 Montanide ISA 51 VG
24 CSP #402 - VA Topical Tretinoin Chemoprevention Trial Completed NCT00007631 Phase 3 Tretinoin 0.1% cream or placebo
25 Chemoprevention of Skin Cancers With DFMO: A Controlled, Randomized Clinical Trial Completed NCT00005884 Phase 3 eflornithine
26 Impact of Preoperative Acetaminophen and Carbohydrate Loading to on Pain and Functional Status in Patients Undergoing Mohs Micrographic Surgery for Non-melanoma Skin Cancers Completed NCT03131713 Phase 3 Acetaminophen
27 A Multicentre, Randomised Study of Photodynamic Therapy(PDT) With Metvix® 160 mg/g Cream in Immuno-compromised Patients With Non-melanoma Skin Cancer Completed NCT00472459 Phase 3
28 A Personalized Approach to Skin Cancer Prevention Among Adolescents Recruiting NCT04341064 Phase 3
29 Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome Recruiting NCT01748448 Phase 3 Vitamin D;arachides oleum raffinatum
30 Melanoma Margins Trial-II - A Phase III, Multi-centre Randomised Controlled Trial Investigating 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma (02.18 MelMarT-II) Recruiting NCT03860883 Phase 3
31 Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma Recruiting NCT02339571 Phase 2, Phase 3
32 DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial Recruiting NCT02224781 Phase 3 Dabrafenib Mesylate;Trametinib Dimethyl Sulfoxide
33 Sun Safe Partners Online: Pilot Randomized Controlled Clinical Trial Active, not recruiting NCT04549675 Phase 3
34 A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma Active, not recruiting NCT02506153 Phase 3
35 A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma Active, not recruiting NCT01274338 Phase 3
36 A Phase III, Multi-centre, Multi-national Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma Active, not recruiting NCT02385214 Phase 3
37 A Phase 3, Randomized, Double-blind Study of BMS-986205 Combined With Nivolumab Versus Nivolumab in Participants With Metastatic or Unresectable Melanoma That is Previously Untreated Active, not recruiting NCT03329846 Phase 3 BMS-986205;Placebo
38 INSPIRE-AYA: A Multicenter Interactive Survivorship Program to Improve Healthcare Resources for Adolescent and Young Adult (AYA) Cancer Survivors Not yet recruiting NCT04593277 Phase 3
39 PV-10 Intralesional Injection vs Systemic Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma Terminated NCT02288897 Phase 3 PV-10 (10% rose bengal disodium);Dacarbazine, temozolomide or talimogene laherparepvec
40 Investigation of the Effectiveness of Non-Coherent Blue Light in Intralesional Photodynamic of Basal Cell Carcinoma Unknown status NCT00747903 Phase 2 aminolevulinic acid hydrochloride
41 Transient Infrared Imaging for Early Detection of Skin Cancer Unknown status NCT02154451 Phase 1, Phase 2
42 A Phase I/II Pilot Study of Bioimmunotherapy With IRESSA (Gefitinib) and Pegylated Interferon Alpha-2a for Patients With Unresectable/Metastatic Squamous Cell Carcinoma of the Skin Unknown status NCT00423397 Phase 1, Phase 2 gefitinib
43 Skin Cancer Prophylaxis by Low-Fat Dietary Intervention Unknown status NCT00003097 Phase 2
44 A Phase 2, Open-Label Evaluation of the Safety and Efficacy of CB-10-01, Transgenic Lymphocyte Immunization (TLI) Against Telomerase, as Adjuvant Therapy in Subjects With Stage III Melanoma Unknown status NCT00925314 Phase 2
45 HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma Unknown status NCT02836548 Phase 1, Phase 2 Vorinostat
46 Phase II Randomized Study of CD34+ Derived or Peripheral Monocyte Derived Dendritic Cells Pulsed With MART-1 and gp100 Melanoma Antigens in Patients With High Risk Stage III or Completely Resected Metastatic Melanoma Completed NCT00019890 Phase 2 dendritic cell-gp100-MART-1 antigen vaccine;sargramostim
47 Phase I/II Pilot Study of Interleukin-12 in Patients With AIDS-Associated Kaposi's Sarcoma Completed NCT00019188 Phase 1, Phase 2 interleukin-12
48 Phase II Study of Allovectin-7 as an Immunotherapeutic Agent in Patients With Stages III and IV Melanoma Completed NCT00003646 Phase 2 allovectin-7
49 Phase II Study of DNA Encoding the gp100 Antigen Alone or in Combination With Interleukin-2 in Patients With Recurrent Metastatic Melanoma Completed NCT00019448 Phase 2 gp100 antigen;interleukin-2
50 Phase II Study of Flt3 Ligand Alone or in Combination With Melanoma Peptide Immunization in Patients With Metastatic Melanoma or Renal Cell Cancer Completed NCT00019396 Phase 2 flt3 ligand;gp100 antigen;MART-1 antigen;Montanide ISA-51;tyrosinase peptide

Search NIH Clinical Center for Skin Benign Neoplasm

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Cholecalciferol
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b

Genetic Tests for Skin Benign Neoplasm

Anatomical Context for Skin Benign Neoplasm

MalaCards organs/tissues related to Skin Benign Neoplasm:

40
Skin, Lymph Node, T Cells, Liver, Lung, Breast, Endothelial

Publications for Skin Benign Neoplasm

Articles related to Skin Benign Neoplasm:

(show top 50) (show all 476)
# Title Authors PMID Year
1
NEAT1 Knockdown Inhibits Keloid Fibroblast Progression by miR-196b-5p/FGF2 Axis. 61
33162101 2021
2
Glaucocalyxin A induces cell cycle arrest and apoptosis via inhibiting NF-κB/p65 signaling pathway in melanoma cells. 61
33577846 2021
3
Adenomatoid tumor of the skin: Differential diagnosis of an umbilical erythematous plaque. 61
32918316 2021
4
A Rare Case of Metastatic Merkel Cell Carcinoma to the Stomach and Pancreas Presenting With Upper Gastrointestinal Bleeding and Obstructive Jaundice. 61
33521158 2021
5
Clinical Impact of FDG PET/CT of the Lower Extremities in Patients With Merkel Cell Carcinoma With Primary Disease Site Outside of the Lower Extremities. 61
33474987 2021
6
Facial microcystic adnexal carcinoma - treatment with a "jigsaw puzzle" advancement flap and immediate esthetic reconstruction: A case report. 61
33553398 2021
7
Atypical fibroxanthoma: A malignant tumor of the skin and soft tissue. 61
32679278 2020
8
The changing paradigm of managing Merkel cell carcinoma in Australia: An expert commentary. 61
32757453 2020
9
A rare case of pleural localization of both metastatic Merkel cell carcinoma and chronic lymphocytic leukemia. 61
33289204 2020
10
Botulinum toxin A as monotherapy for syringoma. 61
33355994 2020
11
Case of Merkel cell carcinoma in a patient with pre-existing ILD. 61
33203666 2020
12
Apocrine mixed tumor of the skin with panfollicular differentiation: A rare case report with immunohistochemical evaluation. 61
32748955 2020
13
The role of insulin-like growth factor in Acrochordon Etiopathology. 61
33143702 2020
14
Solitary sclerotic fibroma on the thigh. 61
33143403 2020
15
Giant Mixed Tumor of the Skin Affecting the Hemiface. 61
32516219 2020
16
Merkel Cell Polyomavirus Small Tumor Antigen Activates Matrix Metallopeptidase-9 Gene Expression for Cell Migration and Invasion. 61
32669331 2020
17
Cutaneous Adenosquamous Carcinoma of the Scalp With Intestinal Phenotype. 61
32379088 2020
18
Surgical treatment of rhinophyma using an ordinary bur. 61
32867419 2020
19
Histopathological Study of Skin Lesions in a Tertiary Care Hospital: A Descriptive Cross-sectional Study. 61
32417857 2020
20
Unusual clinical manifestation of seborrheic keratosis on the scalp successfully treated with topical trichloroacetic acid: an atypical case report. 61
33425131 2020
21
Unmasking dermatofibrosarcoma protuberans: Case report of an atypical presentation complicated by post-surgical excision. 61
32305027 2020
22
The presence of Merkel cell carcinoma polyomavirus is associated with a distinct phenotype in neoplastic Merkel cell carcinoma cells and their tissue microenvironment. 61
32687503 2020
23
Soft tissue sarcoma in neurofibromatosis type 1: A rare case of malignant peripheral nerve sheath tumor of the skin. 61
31964130 2020
24
HI-511 overcomes melanoma drug resistance via targeting AURKB and BRAF V600E. 61
32863956 2020
25
Mixed Tumor of the Nasal Root. 61
32537304 2019
26
Lobular capillary hemangioma in a patient with ankylosing spondylitis using adalimumab: an exuberant presentation. 61
31789263 2019
27
Meningioma-like Tumor of the Skin Revisited: A Distinct CD34+ Dermal Tumor With an Expanded Histologic Spectrum. 61
31490235 2019
28
Fibroblast growth factor receptor promotes progression of cutaneous squamous cell carcinoma. 61
31254372 2019
29
[Erratum to: Malignant collision tumor of the skin : Melanoma, squamous cell carcinoma and basal cell carcinoma]. 61
31312888 2019
30
[Malignant collision tumor of the skin : Melanoma, squamous cell carcinoma and basal cell carcinoma]. 61
31168637 2019
31
Common Nevus and Skin Cutaneous Melanoma: Prognostic Genes Identified by Gene Co-Expression Network Analysis. 61
31557882 2019
32
Merkel Cell Carcinoma of the Digit. 61
31008795 2019
33
Fine-needle aspiration of dermatofibrosarcoma protuberans metastasizing to hemithorax with superior vena cava compression: Case report and literature review. 61
30919592 2019
34
Nasal flap or cutaneous grafting in basal cell cancer of the nose. Comparison of two reconstructive possibilities. 61
32011980 2019
35
Trichofolliculoma of the Eyelid Margin: A Case Report and Review of Literature. 61
30908463 2019
36
Primary Cutaneous Neuroendocrine Carcinoma with Diffuse Expression of Thyroid Transcription Factor-1: Report of Two Cases. 61
31148874 2019
37
Facial distribution of squamous cell carcinoma in Japanese. 61
30698883 2019
38
Malignant Sweat Gland Tumors. 61
30497677 2019
39
[Head & Neck Merkel Cell Carcinoma]. 61
30005427 2019
40
Angiolymphoid hyperplasia with eosinophilia with clinical pictures of keratoacanthoma: A rare case report. 61
30656039 2019
41
Recurrent Merkel cell carcinoma of the gluteal region: A case report. 61
30238578 2019
42
MiR-203 regulates keloid fibroblast proliferation, invasion, and extracellular matrix expression by targeting EGR1 and FGF2. 61
30372829 2018
43
A Case Report of Recurrent Metastatic Sebaceous Carcinoma Which Showed Favorable Response Tt Non-Fluorouracil Based Chemotherapy. 61
30291222 2018
44
Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches. 61
30073632 2018
45
The Ashitaba (Angelica keiskei) Chalcones 4-hydroxyderricin and Xanthoangelol Suppress Melanomagenesis By Targeting BRAF and PI3K. 61
29980517 2018
46
Benign chondroid syringoma affecting the upper lip: Report of a rare case and review of literature. 61
30651687 2018
47
Clinical and pathological study on mixed tumors of the skin. 61
30200138 2018
48
A rare case of hyaline cell-rich atypical chondroid syringoma with divergent differentiation. 61
30004073 2018
49
Recurrent Indeterminate Dendritic Cell Tumor of the Skin. 61
29621879 2018
50
[Clinicopathologic characterization of malignant mixed tumor of the skin accompanied by eccrine porocarcinoma]. 61
29996320 2018

Variations for Skin Benign Neoplasm

Expression for Skin Benign Neoplasm

Search GEO for disease gene expression data for Skin Benign Neoplasm.

Pathways for Skin Benign Neoplasm

Pathways related to Skin Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.37 STAT3 KRT5 KRT20 KRT14 KRT13 KRT1
2
Show member pathways
12.71 STAT3 MSH6 MSH2 MLH1 HRAS
3
Show member pathways
12.53 STAT3 KRT20 KRT14 KRT13 HRAS
4 12.33 XPA TP63 MSH6 MSH2 MLH1
5
Show member pathways
12.29 KRT5 KRT20 KRT14 KRT13 KRT1
6 12.04 STAT3 MSH6 MSH2 MLH1
7
Show member pathways
12.04 STAT3 PTCH1 HRAS GLI2 GLI1
8 12 STAT3 PTCH1 MSH6 MSH2 MLH1 HRAS
9 11.74 KRT20 KRT14 KRT13
10
Show member pathways
11.73 MSH6 MSH2 MLH1
11
Show member pathways
11.7 KRT5 KRT14 KRT13 KRT1
12 11.47 PTCH1 GLI2 GLI1
13 11.33 PTCH1 GLI2 GLI1
14 11.32 XPA MSH6 MSH2 MLH1
15
Show member pathways
11.31 STAT3 MSH2 MLH1
16 11.24 PTCH1 GLI2 GLI1
17 11.06 STAT3 GLI2 GLI1
18 10.72 XPA MSH6 MSH2 MLH1
19
Show member pathways
10.71 PTCH1 GLI2 GLI1

GO Terms for Skin Benign Neoplasm

Cellular components related to Skin Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 keratin filament GO:0045095 9.56 KRT5 KRT14 KRT13 KRT1
2 intermediate filament GO:0005882 9.55 KRT5 KRT20 KRT14 KRT13 KRT1
3 nucleus GO:0005634 9.55 XPA TP63 STAT3 SERPINA3 PTCH1 MSH6
4 MutSalpha complex GO:0032301 9.32 MSH6 MSH2
5 mismatch repair complex GO:0032300 9.13 MSH6 MSH2 MLH1

Biological processes related to Skin Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 10.06 STAT3 HRAS GLI2 GLI1 FGFR3
2 cellular response to DNA damage stimulus GO:0006974 10.04 XPA TP63 MSH6 MSH2 MLH1
3 in utero embryonic development GO:0001701 9.93 PTCH1 MSH2 GLI2 FLCN
4 smoothened signaling pathway GO:0007224 9.8 PTCH1 GLI2 GLI1
5 pattern specification process GO:0007389 9.79 TP63 PTCH1 GLI2
6 epidermis development GO:0008544 9.78 TP63 PTCH1 KRT5 KRT14
7 keratinization GO:0031424 9.77 KRT5 KRT20 KRT14 KRT13 KRT1
8 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.74 MSH6 MSH2 MLH1
9 dorsal/ventral pattern formation GO:0009953 9.71 PTCH1 GLI2 GLI1
10 mismatch repair GO:0006298 9.69 MSH6 MSH2 MLH1
11 positive regulation of DNA replication GO:0045740 9.67 HRAS GLI2 GLI1
12 positive regulation of cell cycle G1/S phase transition GO:1902808 9.65 TP63 GLI1
13 hemidesmosome assembly GO:0031581 9.65 KRT5 KRT14
14 dorsal/ventral neural tube patterning GO:0021904 9.65 PTCH1 GLI2
15 positive regulation of isotype switching to IgG isotypes GO:0048304 9.64 MSH2 MLH1
16 epidermal cell differentiation GO:0009913 9.63 TP63 GLI1
17 smoothened signaling pathway involved in dorsal/ventral neural tube patterning GO:0060831 9.61 PTCH1 GLI2
18 mammary gland duct morphogenesis GO:0060603 9.61 PTCH1 GLI2
19 positive regulation of helicase activity GO:0051096 9.6 MSH6 MSH2
20 positive regulation of isotype switching to IgA isotypes GO:0048298 9.59 MSH2 MLH1
21 maintenance of DNA repeat elements GO:0043570 9.58 MSH6 MSH2
22 smoothened signaling pathway involved in regulation of cerebellar granule cell precursor cell proliferation GO:0021938 9.58 GLI2 GLI1
23 proximal/distal pattern formation GO:0009954 9.58 TP63 GLI2 GLI1
24 prostatic bud formation GO:0060513 9.56 TP63 GLI2
25 cerebellar cortex morphogenesis GO:0021696 9.55 GLI2 GLI1
26 ventral midline development GO:0007418 9.52 GLI2 GLI1
27 isotype switching GO:0045190 9.5 MSH6 MSH2 MLH1
28 notochord regression GO:0060032 9.46 GLI2 GLI1
29 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.43 MSH2 MLH1
30 somatic hypermutation of immunoglobulin genes GO:0016446 9.43 MSH6 MSH2 MLH1
31 cornification GO:0070268 9.35 KRT5 KRT20 KRT14 KRT13 KRT1
32 prostate gland development GO:0030850 9.33 TP63 PTCH1 GLI1
33 somatic recombination of immunoglobulin gene segments GO:0016447 8.8 MSH6 MSH2 MLH1

Molecular functions related to Skin Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.37 XPA TP63 STAT3 SERPINA3 PTCH1 ODC1
2 protein homodimerization activity GO:0042803 9.91 XPA STAT3 ODC1 MSH6 MSH2 GLA
3 transcription regulatory region sequence-specific DNA binding GO:0000976 9.8 TP63 STAT3 GLI2 GLI1
4 chromatin binding GO:0003682 9.73 TP63 MSH6 MSH2 MLH1 GLI2 GLI1
5 MutLalpha complex binding GO:0032405 9.48 MSH6 MSH2
6 oxidized purine DNA binding GO:0032357 9.46 MSH6 MSH2
7 damaged DNA binding GO:0003684 9.46 XPA TP63 MSH6 MSH2
8 single guanine insertion binding GO:0032142 9.4 MSH6 MSH2
9 single thymine insertion binding GO:0032143 9.32 MSH6 MSH2
10 mismatched DNA binding GO:0030983 9.13 MSH6 MSH2 MLH1
11 guanine/thymine mispair binding GO:0032137 8.8 MSH6 MSH2 MLH1

Sources for Skin Benign Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....